Your browser doesn't support javascript.
loading
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.
Witzel, I; Loibl, S; von Minckwitz, G; Eidtmann, H; Fehm, T; Khandan, F; Schmatloch, S; Hauschild, M; Bischoff, J; Fasching, P A; Mau, C; Schem, C; Rack, B; Meinhold-Heerlein, I; Liedtke, C; Karn, T; Huober, J; Zu Eulenburg, C; Issa-Nummer, Y; Untch, M; Müller, V.
Affiliation
  • Witzel I; Department of Gynecology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Br J Cancer ; 107(6): 956-60, 2012 Sep 04.
Article in En | MEDLINE | ID: mdl-22892393

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Breast Neoplasms / Biomarkers, Tumor / Receptor, ErbB-2 / Neoadjuvant Therapy / Antibodies, Monoclonal, Humanized / Antineoplastic Agents Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Br J Cancer Year: 2012 Type: Article Affiliation country: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Breast Neoplasms / Biomarkers, Tumor / Receptor, ErbB-2 / Neoadjuvant Therapy / Antibodies, Monoclonal, Humanized / Antineoplastic Agents Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Br J Cancer Year: 2012 Type: Article Affiliation country: Germany